Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Next Previous
X
Search
Trial Profile

APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patisiran (Primary) ; Clemastine; Famotidine; Retinol
  • Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO-B
  • Sponsors Alnylam Pharmaceuticals

    • Most Recent Events

    • 16 Feb 2024 Planned End Date changed from 1 Jun 2025 to 1 Mar 2027.
    • 13 Nov 2023 Results (n=334 From the Open-Label Extension Period) assessing safety and efficacy of patisiran in Patients With Transthyretin Cardiac Amyloidosis presented at the American Heart Association Scientific Sessions 2023
    • 26 Oct 2023 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top